These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22418877)

  • 1. Positive phase 2 results for immatics colorectal cancer vaccine.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Mar; 8(3):282. PubMed ID: 22418877
    [No Abstract]   [Full Text] [Related]  

  • 2. 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses.
    Durrant LG; Buckley DJ; Robins RA; Spendlove I
    Int J Cancer; 2000 Jan; 85(1):87-92. PubMed ID: 10585589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2/neu as a target for cancer vaccines.
    Baxevanis CN; Voutsas IF; Gritzapis AD; Perez SA; Papamichail M
    Immunotherapy; 2010 Mar; 2(2):213-26. PubMed ID: 20635929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DC-based cancer vaccines: lessons from clinical trials.
    Brody JD; Engleman EG
    Cytotherapy; 2004; 6(2):122-7. PubMed ID: 15203988
    [No Abstract]   [Full Text] [Related]  

  • 5. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer vaccines in clinical trials.
    Speetjens FM; Zeestraten EC; Kuppen PJ; Melief CJ; van der Burg SH
    Expert Rev Vaccines; 2011 Jun; 10(6):899-921. PubMed ID: 21692708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor antigens presented to T helper lymphocytes--critical components of the cancer vaccine].
    Bartnes K
    Tidsskr Nor Laegeforen; 2001 Oct; 121(25):2941-5. PubMed ID: 11715777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
    Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K
    Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
    Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
    Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy.
    van der Burg SH; Bijker MS; Welters MJ; Offringa R; Melief CJ
    Adv Drug Deliv Rev; 2006 Oct; 58(8):916-30. PubMed ID: 16979788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically modified tumour vaccines--where we are today.
    Nawrocki S; Mackiewicz A
    Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine modified tumor vaccines.
    Armstrong TD; Jaffee EM
    Surg Oncol Clin N Am; 2002 Jul; 11(3):681-96. PubMed ID: 12487062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines for colorectal cancer and renal cell carcinoma.
    Kabaker K; Shell K; Kaufman HL
    Cancer J; 2011; 17(5):283-93. PubMed ID: 21952277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New strategies to improve the efficacy of colorectal cancer vaccines: from bench to bedside.
    Mocellin S
    Curr Opin Investig Drugs; 2006 Dec; 7(12):1052-61. PubMed ID: 17209522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.
    Pavlenko M; Leder C; Pisa P
    Expert Rev Vaccines; 2005 Jun; 4(3):315-27. PubMed ID: 16026247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic cancer vaccines based on molecularly defined human tumor antigens.
    Romero P; Pittet M; Dutoit V; Zippelius A; Liénard D; Lejeune F; Guillaume P; Rimoldi D; Valmori D; Speiser DE; Cerottini JC
    Vaccine; 2002 Dec; 20 Suppl 4():A2-7. PubMed ID: 12477422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
    J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4.
    Shingler WH; Chikoti P; Kingsman SM; Harrop R
    Int Immunol; 2008 Aug; 20(8):1057-66. PubMed ID: 18567615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could targeting T-helper cells aid the development of effective cancer vaccines?
    Snook AE
    Immunotherapy; 2014; 6(9):959-61. PubMed ID: 25341117
    [No Abstract]   [Full Text] [Related]  

  • 20. The current status of vaccine development in colorectal cancer.
    Chang DZ
    Clin Adv Hematol Oncol; 2007 Feb; 5(2):109-11, 136. PubMed ID: 17344798
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.